MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies

Dzikiewicz‐Krawczyk, Agnieszka

doi:10.1016/j.critrevonc.2014.08.006

Cited by 21 publications

(16 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These polymorphisms may alter miRNA function as either an oncogene or tumour suppressor and potentially behave as diagnostic and prognostic biomarkers for clinical use. These miRNA variants or SNPs (miRSNPs) have been extensively reviewed in a range of cancer types [20,67,68], including haematological malignancies [29], however no reviews to date have summarised the new research on these miRSNPs in NHL specifically. Currently the significant miRSNPs identified in NHL are very few with even fewer functional studies to back them up and have only been observed in particular subtypes, although in some studies there has been no stratification of subtypes and all patients are classified as NHL.…”

Section: Mirna-related Snps In Nhlmentioning

confidence: 99%

“…Polymorphisms located in the 3′ UTRs of miRNA target genes may affect the precision complementarity and binding affinity between miRNA binding sites and their target mRNAs and therefore disrupt gene expression and protein levels [29]. These SNPs occur more frequently in the genome affecting only target gene expression and its downstream pathway effectors leading to a limited range of effects [68].…”

Section: Mirna-related Snps In Nhlmentioning

confidence: 99%

“…Many researchers are now starting to investigate these SNPs and their functional role in disease susceptibility and outcome. To date, several miRSNPs have been identified in haematological malignancies with only a few so far identified in lymphoma [29]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma

Bradshaw

Sutherland

Haupt

et al. 2016

Genes

View full text Add to dashboard Cite

A large number of studies have focused on identifying molecular biomarkers, including microRNAs (miRNAs) to aid in the diagnosis and prognosis of the most common subtypes of non-Hodgkin lymphoma (NHL), Diffuse Large B-cell Lymphoma and Follicular Lymphoma. NHL is difficult to diagnose and treat with many cases becoming resistant to chemotherapy, hence the need to identify improved biomarkers to aid in both diagnosis and treatment modalities. This review summarises more recent research on the dysregulated miRNA expression profiles found in NHL, as well as the regulatory role and biomarker potential of cellular and circulating miRNAs found in tissue and serum, respectively. In addition, the emerging field of research focusing on miRNA single nucleotide polymorphisms (miRSNPs) in genes of the miRNA biogenesis pathway, in miRNA genes themselves, and in their target sites may provide new insights on gene expression changes in these genes. These miRSNPs may impact miRNA networks and have been shown to play a role in a host of different cancer types including haematological malignancies. With respect to NHL, a number of SNPs in miRNA-binding sites in target genes have been shown to be associated with overall survival.

show abstract

Section: Mirna-related Snps In Nhlmentioning

confidence: 99%

Section: Mirna-related Snps In Nhlmentioning

confidence: 99%

See 1 more Smart Citation

Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma

Bradshaw

Sutherland

Haupt

et al. 2016

Genes

View full text Add to dashboard Cite

show abstract

“…A growing number of miRNAs related causative SNPs were identified [102]. Disease susceptibility associated miRSNPs have attracted growing interests [103]. However, knowledge about the pharmacogenomic significance of the miRSNPs is scarce.…”

Section: Mirsnps Modify Cancer Chemotherapy Response and Survivalmentioning

confidence: 99%

MiRNAs and miRNA Polymorphisms Modify Drug Response

et al. 2016

IJERPH

View full text Add to dashboard Cite

Differences in expression of drug response-related genes contribute to inter-individual variation in drugs’ biological effects. MicroRNAs (miRNAs) are small noncoding RNAs emerging as new players in epigenetic regulation of gene expression at post-transcriptional level. MiRNAs regulate the expression of genes involved in drug metabolism, drug transportation, drug targets and downstream signal molecules directly or indirectly. MiRNA polymorphisms, the genetic variations affecting miRNA expression and/or miRNA-mRNA interaction, provide a new insight into the understanding of inter-individual difference in drug response. Here, we provide an overview of the recent progress in miRNAs mediated regulation of biotransformation enzymes, drug transporters, and nuclear receptors. We also describe the implications of miRNA polymorphisms in cancer chemotherapy response.

show abstract

“…Polymorphisms in miRNA‐binding sites in target genes may alter the strength of miRNA–mRNA interactions, thus deregulating protein expression. SNPs belonging to this category are called miRSNPs . MiRSNPs have been shown to be associated with the risk of several cancers …”

mentioning

confidence: 99%

Identification of miRSNPs associated with the risk of multiple myeloma

et al. 2016

View full text Add to dashboard Cite

Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. Multiple lines of evidence suggest that genetic factors are involved in MM pathogenesis, and several studies have identified single nucleotide polymorphisms (SNPs) associated with the susceptibility to the disease. SNPs within miRNA-binding sites in target genes (miRSNPs) may alter the strength of miRNA-mRNA interactions, thus deregulating protein expression. MiRSNPs are known to be associated with risk of various types of cancer, but they have never been investigated in MM. We performed an in silico genome-wide search for miRSNPs predicted to alter binding of miRNAs to their target sequences. We selected 12 miRSNPs and tested their association with MM risk. Our study population consisted of 1,832 controls and 2,894 MM cases recruited from seven European countries and Israel in the context of the IMMEnSE (International Multiple Myeloma rESEarch) consortium. In this population two SNPs showed an association with p < 0.05: rs286595 (located in gene MRLP22) and rs14191881 (located in gene TCF19). Results from IMMEnSE were meta-analyzed with data from a previously published genome-wide association study (GWAS). The SNPs rs13409 (located in the 3'UTR of the POU5F1 gene), rs1419881 (TCF19), rs1049633, rs1049623 (both in DDR1) showed significant associations with MM risk. In conclusion, we sought to identify genetic polymorphisms associated with MM risk starting from genome-wide prediction of miRSNPs. For some mirSNPs, we have shown promising associations with MM risk.

show abstract

MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies

Cited by 21 publications

References 65 publications

Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma

Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma

MiRNAs and miRNA Polymorphisms Modify Drug Response

Identification of miRSNPs associated with the risk of multiple myeloma

Contact Info

Product

Resources

About